Skip to main content

Table 1 Clinical characteristics of pediatric untreated acute and IVIG-treated subacute and convalescent KD subjects and healthy and febrile controls

From: Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children

Characteristic Acute KD
2–10 days
(n = 75)
Subacute KD
13–24 days
(n = 36)
Early Convalescent KD
25–75 days
(n = 43)
Late Convalescent KD
9–49 months
(n = 20)
Acute Febrile Controls
Bacterial origin
(n = 12)
Acute Febrile Controls
Viral origin
(n = 36)
Healthy
Controls
(n = 48)
Male, n (%) 39 (52) 20 (56) 26 (60) 11 (55) 10 (83) 21 (58)
Age, years 3.6 (1.8–5.0) 2.9 (1.7–4.6) 3.1 (1.7–4.5) 8.0 (6.7–9.2) 6.2 (4.7–8.2) 2.8 (1.6–5.3) 4.7 (3.0–6.6)
Illness day/month 6.0 d (4.5–7.0) 19 d (16–21) 48 d (34–55) 16 m (14–29) 3.5 d (3.0–4.3) 6.0 d (4.0–6.3)
Median lab values
 WBC, ×103/μL 13.7 (10.6–17.3) 7.3 (6.8–9.0) 7.4 (6.0–8.5) 12.4 (10.1–14.5)# 8.7 (6.3–11.5)#
 PMN, % 56 (45–66) 37 (26–50) 37 (27–42) 62 (46–70) 40 (23–54)
 ANC, cells/μL 9646 (6693–12,131) 3025 (1953–3950) 2516 (1823–3525) 7014 (5565–9444) 3408 (2071–6764)
 ESR, mm/h 61 (47–75) 37 (31–57) 17 (9–31) 31 (22–40)# 30 (17–39)#
 CRP, mg/dL 7.4 (4.7–16.7) 0.3 (0.3–0.8) 0.3 (0.3–0.3) 2.2 (1.0–8.6)# 4.1 (2.2–5.0)#
 GlycA, μmol/L 808 (693–919) 440 (382–512) 309 (272–377) 341 (319–395) 595 (571–745) 611 (551–702) 319 (290–354)
  1. Median (IQR = Interquartile Range; 25th-75th percentile); KD Kawasaki Disease, d days, m months, WBC white blood cell count, PMN polymorphonuclear cells, ANC absolute neutrophil count, ESR erythrocyte sedimentation rate, CRP C-reactive protein; GlycA, NMR-measured marker of systemic inflammation. #Lab data available for WBC 46 subjects, ESR 42 subjects, CRP 31 subjects
  2. Acute KD samples were taken pre-IVIG treatment. All other KD samples were taken post-IVIG treatment